Candel Therapeutics Reports 24.5-Month Survival in Lung Cancer Trial
Phase 2a data shows aglatimagene plus valacyclovir more than doubled typical survival benchmarks for hard-to-treat late-stage NSCLC patients.
Candel Therapeutics announced Wednesday the publication of final Phase 2a clinical trial results showing its experimental gene-based immunotherapy combination achieved a median overall survival of 24.5 months in patients with unresectable Stage III or IV non-small cell lung cancer who had not responded adequately to immune checkpoint inhibitor therapy.
The Needham, Massachusetts-based biopharmaceutical company said the survival figure substantially exceeded historical benchmarks associated with standard-of-care docetaxel chemotherapy, a second-line treatment commonly used in this difficult-to-treat patient population. The trial, registered as NCT04495153, evaluated the combination of aglatimagene besadenovec and the antiviral drug valacyclovir.
Read more Sigo Seguros Opens Auto Insurance MCP Server to AI Chatbots →
Candel, which trades on Nasdaq under the ticker CADL, is a clinical-stage company focused on multimodal immunotherapies — treatments designed to engage multiple pathways of the immune system simultaneously to fight cancer. The mechanism behind the combination is described by the company as systemic immune reactivation, suggesting the therapy may restore or amplify anti-tumor immune responses in patients whose cancers had previously evaded checkpoint inhibitor drugs.
Late-stage NSCLC patients with inadequate responses to immune checkpoint inhibitors represent a significant unmet medical need, as their options after first-line treatment failure are limited and outcomes with existing therapies remain poor. The publication of final trial data in this indication marks a key milestone for the company as it pursues further development of aglatimagene besadenovec.
Continue reading at GlobeNewswire - Industry News on Financial Services.
